Efruxifermin treatment led to a significant reduction in hepatic steatosis of −14.1% and reduced ALT levels by −32.3 U/L, liver stiffness by −37.6 kPa, and fibrosis biomarkers such as pro-C3 by −8.4 μg/L. This evidence concerns the gene GPT and Hepatic steatosis.